"Designing Growth Strategies is in our DNA"

Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review,2019

Region : Global | Report ID: FBI100656

 

KEY MARKET INSIGHTS

Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation caused due to accumulation of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) demonstrate very few or no symptoms at the initial stages. Some symptoms such as fatigue, weight loss, general weakness and ache in the upper right part of belly are observed at later stages. The exact cause of NASH is unknown, but some of the common causes include obesity, type 2 diabetes, high cholesterol & triglycerides and metabolic syndrome.


Currently, there are no treatments available of non-alcoholic steatohepatitis (NASH). The first line of treatment is weight loss through a combination of a healthy diet and exercise. In February 2019, Intercept Pharmaceuticals, Inc., announced positive topline results from pivotal phase 3 regenerate study of obeticholic acid in patients with liver fibrosis due to NASH.


Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for non-alcoholic steatohepatitis (NASH) treatment. For instance, Seladelpar, which is being studied by CymaBay Therapeutics, Inc., is currently in phase-2 clinical trials for the study to evaluate seladelpar in subjects with nonalcoholic steatohepatitis (NASH)


To know how our report can help streamline your business, Speak to Analyst


At present around 50% of the pipeline candidates for non-alcoholic steatohepatitis (NASH) treatment are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.


Report Description


The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for non-alcoholic steatohepatitis (NASH) treatment. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, and description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for non-alcoholic steatohepatitis (NASH) treatment.


The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.


Report Scope



  • Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target

  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration

  • Overview of dormant and discontinued pipeline products

  • Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products

  • Overview of the latest developments; news articles, press releases and relevant conferences 


Report Methodology



  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.

  • Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 


Reasons to Buy this Report



  • Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for non-alcoholic steatohepatitis (NASH) treatment

  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players

  • Identify the focus of leading players in relation to R&D for non-alcoholic steatohepatitis (NASH) treatment

  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business

  • Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary 


Non-alcoholic Steatohepatitis Treatment Market  Review

    CHOOSE LICENSE TYPE

  • 2850
    4850
    6850

Healthcare Clients

Ge-Healthcare
DAEWOONG
chong-kun-dang
Bio-Rad
Logo_Merck_KGaA_2015

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X